Cart
sales@molnova.com
JAK3-IN-14
CAS No. 454234-24-3
JAK3-IN-14( —— )
Catalog No. M35961 CAS No. 454234-24-3
JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ～40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 407 | In Stock |
|
| 5MG | 454 | In Stock |
|
| 10MG | 660 | In Stock |
|
| 25MG | 1007 | In Stock |
|
| 50MG | 1330 | In Stock |
|
| 100MG | 1795 | In Stock |
|
| 200MG | 2399 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJAK3-IN-14
-
NoteResearch use only, not for human use.
-
Brief DescriptionJAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ～40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.
-
DescriptionJAK3-IN-14 (compound 1) is a potent JAK3 inhibitor, with IC50 values of 38 and 600 nM for JAK3 and JAK2, respectively. JAK3-IN-14 shows inhibitory of IL-4 and IL-3 induced TF-1 cell proliferation, with IC50 values of 600 and 500 nM, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetFLT
-
RecptorFLT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number454234-24-3
-
Formula Weight287.32
-
Molecular FormulaC18H13N3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (435.05 mM; Ultrasonic )
-
SMILESC(=C1C=2C(NC1=O)=CC=C(C2)C=3C=CC=NC3)C4=CC=CN4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chen JJ, et al. Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5633-8.?
molnova catalog
related products
-
XL019
XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM.
-
HPK1-IN-2
HPK1-IN-2 is a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1;IC50<0.05 μΜ).?
-
4SC-203
4SC-203 is a multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs).
